We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
ICH (International Council for Harmonization) recently adopted (1 Nov 2019) the guideline Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. This guideline includes two annexes and aims to “promote innovation and continued improvement in the pharmaceutical sector”.
Change is a natural occurrence over lifecycle due to evolving knowledge, improved understanding about processes and systems, and efforts on continuous improvement. Q12 is focused on the commercial phase of the lifecycle of a drug substance, drug product, and drug-device combination product. The FDA is encouraging use of Q12, as it is compatible with their legal framework. Moreover, Q12 allows flexibility for post-approval CMC (chemistry, manufacturing, controls) changes based upon the effectiveness of a company’s PQS (pharmaceutical quality system) and risked-based change management system. The extent of this flexibility depends on several factors: (a) amount of product and process understanding;, (b) application of QRM (quality risk management) principles;, and (c) effective quality system (ICH Q8 (R2), ICH Q9, ICH Q10 and ICH Q11).
Some of the key new concepts introduced are:
Leveraging Q12 is an excellent way to better explain to regulatory agencies the understanding of greatest risks and the ongoing management of a product through its lifecycle. Note that in Europe rework of some local regulations must be performed in order to fully implement some of the concepts of Q12.
Click here to read the Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management.
Part 2 will consider some of the key new concepts of Q12 in more detail.
Join West’s Diane Paskiet at the 2013 PDA/FDA Container Closure Components and Systems Workshop:<em>Protecting Parenteral Drugs and Biologics Using Suitable Container Closure Systems,</em> on May 14-15, 2013, at the Hyatt Regency Bethesda in Bethesda, Maryland.
In 2014, the West Women Investing and Networking (WIN) initiative was born under the leadership of Karen Flynn, Sr. VP & Chief Commercial Officer, and a group of female employees at the West U.S. headquarters in Exton.
As members of the pharmaceutical community, we’re often keenly aware of regional regulatory differences. But it’s just as useful to focus on points of harmony, whether these are well-established, emerging, or implicit in regulatory and industry feedback.
Since our Eschweiler’s site founding in 1960 as Pharma-Gummi, we have been helping to support our overall company mission to ensure the development and delivery of lifesaving, life-enhancing medicines for patients around the world. In the current COVID-19 pandemic, we have a special role to play: through these challenging times, vaccine developers have trusted West as a partner of choice to help protect their sensitive biomolecules. If you’ve ever been vaccinated, or if you or a loved one has ever needed to take an injected medicine, you’ve probably encountered a West product.
<p>We are very pleased to introduce our newly redesigned and enhanced website: <a href="https://www.westpharma.com">www.westpharma.com</a>. </p><p>Our commitment to customers guides everything that we do – and our website is no different. The new and improved site offers a fresh look with easy navigation, mobile optimization and expanded digital capabilities to improve the customer experience.</p>
English
Chinese
